Geron Corporation $GERN Stake Increased by Inspire Investing LLC

Inspire Investing LLC grew its holdings in Geron Corporation (NASDAQ:GERN) by 28.9% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 284,724 shares of the biopharmaceutical company’s stock after purchasing an additional 63,789 shares during the period. Inspire Investing LLC’s holdings in Geron were worth $401,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Frisch Financial Group Inc. raised its holdings in shares of Geron by 84.3% during the first quarter. Frisch Financial Group Inc. now owns 19,025 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 8,700 shares in the last quarter. Focus Partners Advisor Solutions LLC purchased a new stake in shares of Geron during the first quarter worth $39,000. StoneCrest Wealth Management Inc. purchased a new stake in shares of Geron during the second quarter worth $35,000. Sowell Financial Services LLC purchased a new stake in shares of Geron during the first quarter worth $43,000. Finally, Summit Financial Strategies Inc. purchased a new stake in shares of Geron during the second quarter worth $38,000. Hedge funds and other institutional investors own 73.71% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on GERN shares. The Goldman Sachs Group started coverage on Geron in a report on Thursday, July 10th. They set a “sell” rating and a $1.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Geron in a report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Geron presently has a consensus rating of “Hold” and an average target price of $3.79.

Geron Price Performance

NASDAQ GERN opened at $1.27 on Tuesday. Geron Corporation has a fifty-two week low of $1.09 and a fifty-two week high of $4.50. The stock’s 50-day moving average is $1.36 and its two-hundred day moving average is $1.37. The company has a debt-to-equity ratio of 0.46, a current ratio of 7.87 and a quick ratio of 6.79. The firm has a market cap of $810.29 million, a P/E ratio of -9.77 and a beta of 0.57.

Geron (NASDAQ:GERN) last posted its earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.01. Geron had a negative return on equity of 31.37% and a negative net margin of 53.52%.The company had revenue of $49.04 million for the quarter, compared to analyst estimates of $47.30 million. During the same period last year, the company earned ($0.10) earnings per share. The business’s revenue was up 5455.6% compared to the same quarter last year. On average, analysts anticipate that Geron Corporation will post -0.25 earnings per share for the current fiscal year.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.